Abstract
Total bakkenolides is the major component of the rhizome of Petasites trichinous Franch.. In this study, we investigated its neuroprotective effects in a rat transient focal cerebral ischemia-reperfusion model, and in an in vitro cerebral ischemia model, oxygen-glucose deprivation of cultured nerve cells. Oral administration of total bakkenolides immediately after reperfusion at doses of 5, 10 and 20 mg/kg markedly reduced brain infarct volume and neurological deficits. Total bakkenolides significantly attenuated cell death and apoptosis in primarily cultured neurons subject to 1-h hypoxia followed by 24-h reoxygenation. Morphologic observations directly confirmed its protective effect on neurons. We also demonstrated that total bakkenolides could inhibit nuclear factor-κB (NF-κB) activation by blocking the classic activation pathway through suppression of phosphorylation of IκB-kinase complex, NF-κB/p65 and inhibitor protein IκB, inducing nuclear translocation of NF-κB/p65 and degradation of IκB. Further, total bakkenolides inhibited the activation of Akt and the extracellular signal-regulated kinase 1/2, two important upstream activators of NF-κB. In conclusion, our results provide a strong pharmacological basis for further understanding the potential therapeutic role of total bakkenolides in cerebral ischemic disease and shed new light on its neuroprotective mechanism.
Keywords: Total bakkenolides; cerebral ischemia; neuroprotection; mechanism; nuclear factor-κB.
CNS & Neurological Disorders - Drug Targets
Title:Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation
Volume: 13 Issue: 5
Author(s): Qian Jiang, Yu-Ye Xia, Jian-Ming He, Mei-li Guo and Run-Ping Li
Affiliation:
Keywords: Total bakkenolides; cerebral ischemia; neuroprotection; mechanism; nuclear factor-κB.
Abstract: Total bakkenolides is the major component of the rhizome of Petasites trichinous Franch.. In this study, we investigated its neuroprotective effects in a rat transient focal cerebral ischemia-reperfusion model, and in an in vitro cerebral ischemia model, oxygen-glucose deprivation of cultured nerve cells. Oral administration of total bakkenolides immediately after reperfusion at doses of 5, 10 and 20 mg/kg markedly reduced brain infarct volume and neurological deficits. Total bakkenolides significantly attenuated cell death and apoptosis in primarily cultured neurons subject to 1-h hypoxia followed by 24-h reoxygenation. Morphologic observations directly confirmed its protective effect on neurons. We also demonstrated that total bakkenolides could inhibit nuclear factor-κB (NF-κB) activation by blocking the classic activation pathway through suppression of phosphorylation of IκB-kinase complex, NF-κB/p65 and inhibitor protein IκB, inducing nuclear translocation of NF-κB/p65 and degradation of IκB. Further, total bakkenolides inhibited the activation of Akt and the extracellular signal-regulated kinase 1/2, two important upstream activators of NF-κB. In conclusion, our results provide a strong pharmacological basis for further understanding the potential therapeutic role of total bakkenolides in cerebral ischemic disease and shed new light on its neuroprotective mechanism.
Export Options
About this article
Cite this article as:
Jiang Qian, Xia Yu-Ye, He Jian-Ming, Guo Mei-li and Li Run-Ping, Total Bakkenolides Protects Neurons Against Cerebral Ischemic Injury Through Inhibition of Nuclear Factor-κB Activation, CNS & Neurological Disorders - Drug Targets 2014; 13 (5) . https://dx.doi.org/10.2174/18715273113129990104
DOI https://dx.doi.org/10.2174/18715273113129990104 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiovascular Molecular Imaging: New Methodological Strategies
Current Pharmaceutical Design The Effects of Erythropoietin on the Respiratory Function: Measurements of Respiratory Mechanics in the Rat
Current Respiratory Medicine Reviews Diabetes Mellitus: Channeling Care through Cellular Discovery
Current Neurovascular Research Epigenetic Regulation Through SIRT1 in Podocytes
Current Hypertension Reviews ULK1 Plays a Critical Role in AMPK-Mediated Myocardial Autophagy and Contractile Dysfunction following Acute Alcohol Challenge
Current Pharmaceutical Design Conference Report [IANR V and 9th GCNN Conference with 4th ISCITT Symposium]
CNS & Neurological Disorders - Drug Targets Pathophysiology of Myocardial Infarction and Acute Management Strategies
Cardiovascular & Hematological Agents in Medicinal Chemistry Distribution, Metabolism, Excretion and Toxicokinetics of Vitexin in Rats and Dogs
Current Pharmaceutical Analysis The Molecular Basis of Conantokin Antagonism of NMDA Receptor Function
Current Drug Targets Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Nanofibre Based Smart Pharmaceutical Scaffolds for Wound Repair and Regenerations
Current Pharmaceutical Design Updated Electrocardiographic Classification of Acute Coronary Syndromes
Current Cardiology Reviews Heat Shock Proteins in Diabetes and Wound Healing
Current Protein & Peptide Science Beclin 1 Biology and its Role in Heart Disease
Current Cardiology Reviews MicroRNA-mediated Regulation of Angiogenesis
Current Angiogenesis (Discontinued) Membrane Localization of Estrogen Receptors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Isosteviol Protects H9c2 Cells Against Hypoxia-reoxygenation by Activating ERK1/2
Cardiovascular & Hematological Disorders-Drug Targets Perinatal Brain Injury
Current Pediatric Reviews Role of Nitrosative Stress and Poly(ADP-ribose) Polymerase Activation in Myocardial Reperfusion Injury
Current Vascular Pharmacology Metabolic Therapy: Lessons from Liver Diseases
Current Pharmaceutical Design